# US 8,569,229 B2 · Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,229 B2
- Document ID: US8569229B2
- Status: Granted
- Kind: B2
- Application number: 12/852,711
- Filed: 2010-08-09
- Published: 2011-01-13
- Granted: 2013-10-29
- Earliest claimed: 2008-02-07
- Assignees: The Children's Hospital of Philadelphia
- Applicants: Michael M. Grunstein
- Inventors: Michael M. Grunstein
- Web page: https://patentgrep.com/patent/US8569229B2

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/365: Lactones
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 38/1709: {from mammals}
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 17/00: Drugs for dermatological disorders
- A61P 27/02: Ophthalmic agents
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.

## Claims

### Claim 1

A method for the treatment of asthma in a patient in need thereof, comprising administration of an effective amount of an inhibitor of G βγ signaling, said administration being effective to reduce bronchoconstriction in said patient, wherein said inhibitor of G βγ signaling is a membrane permeable G βγ blocking peptide comprising SEQ ID NO: 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein asthma in said patient is exacerbated by long term use of β2-adrenergic receptor agonists.

### Claim 3 (depends on 1)

The method of claim 1 wherein said inhibitor of G βγ signaling is delivered to a patient by a method selected from the group consisting of systemic, oral, intravenous, intramuscular, subcutaneous, intraorbital, intranasal, intracapsular, intraperitoneal, intracisternal, intratracheal, intraarticular administration, and absorption through the skin.

### Claim 4 (depends on 1)

The method of claim 1, wherein said inhibitor of G βγ signaling is formulated for aerosol delivery and is delivered via inhalation.

### Claim 5 (depends on 4)

The method of claim 4, wherein said aerosolized formulation comprises a propellant selected from the group consisting of halocarbons, hydrocarbons and esters.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administration of at least one anti-inflammatory agent selected from the group consisting of corticosteroids, sodium cromolyn, IgE inhibitors, phosphodiesterase inhibitors, methylxanthines, beta-adrenergic agents, and leukotriene modifiers.

### Claim 7 (depends on 6)

The method of claim 6, wherein said anti-inflammatory agent is delivered simultaneously with said inhibitor of G βγ signaling.

### Claim 8 (depends on 6)

The method of claim 6, wherein said anti-inflammatory agent is delivered sequentially, before or after delivery of said inhibitor of G βγ signaling.